Skip to main content

Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.